Do recombinant antigens have a future as diagnostic markers for Invasive Aspergillosis?

Sarfati J.1, Monod M.2, Recco P.3, Sulahian A.4, Latgé J-P.1

Full title: 

Do recombinant antigens have a future as diagnostic markers for Invasive Aspergillosis?

Author address: 

1Institut Pasteur, Paris France 2CHUV, Lausanne, Switzerland 3CHU Toulouse, France 4Hopital St Louis Paris, France

Abstract: 

Recombinant proteins of Aspergillus fumigatus were tested by ELISA to quantify the anti-Aspergillus antibodies in sera of patients with aspergilloma and invasive aspergillosis (IA). In spite of the variability observed in the immune reponses of individual patients, quantification of the antibody titers against the 18-kDa ribonuclease, the 360-kDa catalase and the 88 kDa dipeptidylpeptidaseV were useful for the diagnosis of aspergilloma. In the group of immunocompromised patients with IA, no antibody response was mounted in response to the Aspergillus infection in any of the patients. Interestingly, about half of the patients with proven IA came to the hospital with high titers of anti-Aspergillus antibodies, suggesting that they were infected upon entry to the hospital. These results suggest that recombinant ribonuclease, catalase and dipeptidylpeptidaseV have a great potential in the serodiagnosis of aspergillosis in the immunocompromised and immunocompetent patient.
2006
    • AAA 2nd (2006)

abstract No: 

P059

Full conference title: 

2nd Advances against Aspergillosis